Alector Reports Recent Business Highlights and Second Quarter 2019 Financial Results

Alector Announces the Addition of Kristine Yaffe, M.D., to the Board of Directors

Alector Announces Data from On-going Phase 1b Trial Demonstrating that AL001 Reverses Progranulin Deficiency in Frontotemporal Dementia Patients

Alector Announces Upcoming Presentations at 2019 Alzheimer's Association International Conference

Alector Reports Recent Business Highlights and First Quarter 2019 Financial Results

Alector to Present at the Bank of America Merrill Lynch Healthcare Conference on May 15, 2019

Alector Announces First Alzheimer’s Disease Patient Dosed in Phase 1b Study of AL002

Alector Announces First Frontotemporal Dementia Patient Dosed in Phase 1b Study of AL001

Alector Initiates Phase 1 Trial of AL003 for the Treatment of Patients with Alzheimer’s Disease

Alector Reports Recent Business Highlights and Fourth Quarter and Full Year 2018 Financial Results